TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07113262: A Multicenter, Randomized, Double-masked, Placebo-controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of IBI311 in Subjects With Inactive Thyroid Eye Disease

Sponsor: Innovent Biologics (Suzhou) Co. Ltd. · Phase: PHASE3 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 111 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$15,086,080

Rescue Site Savings

+$9,947,384

Unlock Full NCT07113262 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07113262 Rescue Dossier →